Morning Edition · Tuesday, June 30, 2026
United States Medicare Begins Covering Obesity Drugs for the First Time
A new program starting July 1 opens access to weight-loss medicines for millions of older Americans, expanding the market for Novo Nordisk and Eli Lilly.
The United States Medicare program, which covers older and disabled Americans, will begin covering obesity medicines on July 1 for the first time, under a demonstration program that runs through the end of 2027, according to CNBC. Eligible beneficiaries will be able to obtain glucagon-like peptide-1 (GLP-1) drugs, the class of weight-loss medicines that includes Novo Nordisk's Wegovy and Eli Lilly's Zepbound, for a copay of about 50 dollars a month.
Under the arrangement, which stems from a deal the Trump administration announced with the two drugmakers, the government will pay about 245 dollars for a month's supply. The Kaiser Family Foundation estimates that about 3.8 million beneficiaries, roughly 8 percent of the relevant enrollees, could be eligible.
The change could bring in millions of new patients for the manufacturers while adding a significant new cost to a public program. Physicians have warned that prior-authorization requirements and a sharp rise in demand could strain clinics and pharmacies.
Part of a tracked trend
Insurance Opens the Mass Market for Weight-Loss Drugs
Expanding public and private insurance coverage steadily converts obesity drugs into a mass market, driving recurring revenue growth for their makers and rising costs for health systems.
What this means
Public insurance coverage transforms obesity drugs from a cash-payment product into a mass market, a major revenue expansion for Novo Nordisk and Eli Lilly and a meaningful new area of federal spending. How the demonstration is priced and rationed will shape both the companies' growth and the public cost of a rapidly growing category in medicine.
What to watch
- Take-up rates among eligible Medicare beneficiaries, the figure that determines both company revenue and program cost.
- Whether the negotiated price holds or shifts as volumes rise, a test of the government's leverage with the drugmakers.
- Supply and manufacturing capacity at Novo Nordisk and Eli Lilly, since demand could exceed production.
Observations to monitor, not financial advice.
More from this edition
- Yen Falls to Four-Decade Low Against the Dollar as Tokyo Weighs Intervention
- Washington and Tehran Give Conflicting Accounts of Planned Doha Talks
- China Squeezes Japan on Rare Earths as the European Union Sets a Trade Deadline
- Russian Banks Post Record Payouts as Their Chief Executive Warns on the Economy
- Venezuela's Earthquake Toll Passes 1,700 as Aid and Food Run Short
- European Heatwave Drives Up Power Demand as Health Officials Warn of Worse to Come
- Keiko Fujimori Wins Peru's Presidency by About 50,000 Votes
- Britain Unveils Defense Plan Built Around Drones and Uncrewed Vehicles
- Indonesia Pushes Market Reforms While Deepening Ties With Russia
- United States Regulator Wins 5.5 Million Dollar Judgment Over Alleged Crypto Scam
- Explosion in Monaco Injures Ukrainian Businessman as Suspect Flees to France